MiR-146b attenuates high-fat diet-induced non-alcoholic steatohepatitis in mice

Journal of Gastroenterology and Hepatology (Australia)

Volumn 30, Issue 5, 2015, Pages 933-943

  Jiang, Weiwei ^a   Liu, Juan ^a   Dai, Yanyan ^a   Zhou, Nan ^a   Ji, Chenling ^a   Li, Xiaonan ^a  

^a CHILDREN S HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

Author keywords

IL 1 receptor associated kinase 1 (IRAK1); MiR 146b; Non alcoholic steatohepatitis; Toll like receptor signaling; Tumor necrosis factor receptor associated factor 6 (TRAF6)

Indexed keywords

CYTOKINE; EOSIN; HEMATOXYLIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 1; LIPOPOLYSACCHARIDE; MESSENGER RNA; MICRORNA; MICRORNA 146B; OLEIC ACID; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6; UNCLASSIFIED DRUG; AUTACOID; FAT INTAKE; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE; IRAK1 PROTEIN, MOUSE; MIRN146 MICRORNA, MOUSE;

ADIPOSE TISSUE CELL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; EXPERIMENTAL MODEL; HEPG2 CELL LINE; HIGH FAT DIET INDUCED NON ALCOHOLIC STEATOHEPATITIS; IN VITRO STUDY; IN VIVO STUDY; LIPID DIET; LIPID STORAGE; MACROPHAGE; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; STAINING; UPREGULATION; ADVERSE EFFECTS; ANIMAL; C57BL MOUSE; CELL LINE RAW 264.7; DISEASE MODEL; FAT INTAKE; GENETICS; HUMAN; LIPID METABOLISM; LIVER; MALE; METABOLISM; NON-ALCOHOLIC FATTY LIVER DISEASE;

ANIMALS; CYTOKINES; DIET, HIGH-FAT; DIETARY FATS; DISEASE MODELS, ANIMAL; HEP G2 CELLS; HUMANS; INFLAMMATION MEDIATORS; INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES; LIPID METABOLISM; LIVER; MALE; MICE; MICE, INBRED C57BL; MICRORNAS; NF-KAPPA B; NON-ALCOHOLIC FATTY LIVER DISEASE; RAW 264.7 CELLS; TNF RECEPTOR-ASSOCIATED FACTOR 6;

EID: 84926636737     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.12878     Document Type: Article

References (29)

1. Day CP, James OF. Steatohepatitis: a tale of two "hits"? Gastroenterology 1998; 114: 842-845.
2. Day CP. From fat to inflammation. Gastroenterology 2006; 130: 207-210.
3. Rivera CA, Adegboyega P, van Rooijen N, Tagalicud A, Allman M, Wallace M. Toll-like receptor-4 signaling and Kupffer cells play pivotal roles in the pathogenesis of non-alcoholic steatohepatitis. J. Hepatol. 2007; 47: 571-579.
4. Spruss A, Kanuri G, Wagnerberger S, Haub S, Bischoff SC, Bergheim I. Toll-like receptor 4 is involved in the development of fructose-induced hepatic steatosis in mice. Hepatology 2009; 50: 1094-1104.
5. Li L, Chen L, Hu L etal. Nuclear factor high-mobility group box1 mediating the activation of Toll-like receptor 4 signaling in hepatocytes in the early stage of nonalcoholic fatty liver disease in mice. Hepatology 2011; 54: 1620-1630.
6. Sieling PA, Modlin RL. Activation of Toll-like receptors by microbial lipoproteins. Scand. J. Infect. Dis. 2001; 33: 97-100.
7. Tsan MF, Gao B. Endogenous ligands of Toll-like receptors. J. Leukoc. Biol. 2004; 76: 514-519.
8. Takeda K, Akira S. TLR signaling pathways. Semin. Immunol. 2004; 16: 3-9.
9. Seki E, Brenner DA. Toll-like receptors and adaptor molecules in liver disease: update. Hepatology 2008; 48: 322-335.
10. Akira S, Takeda K. Toll-like receptor signaling. Nat. Rev. Immunol. 2004; 4: 499-511.
11. Ambros V. The functions of animal microRNAs. Nature 2004; 431: 350-355.
12. Taganov KD, Boldin MP, Chang KJ, Baltimore D. NF-kappaB dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc. Natl. Acad. Sci. U.S.A. 2006; 103: 12481-12486.
13. O'Neill LA, Sheedy FJ, McCoy CE. MicroRNAs: the fine-tuners of Toll-like receptor signalling. Nat. Rev. Immunol. 2011; 11: 163-175.
14. Hulsmans M, Van Dooren E, Mathieu C, Holvoet P. Decrease of miR-146b-5p in monocytes during obesity is associated with loss of the anti-inflammatory but not insulin signaling action of adiponectin. PLoS ONE 2012; 7: e32794.
15. Bhaumik D, Scott GK, Schokrpur S etal. MicroRNAs miR-146a/b negatively modulate the senescence-associated inflammatory mediators IL-6 and IL-8. Aging (Albany NY) 2009; 1: 402-411.
16. Elsarraj HS, Hong Y, Valdez K etal. A novel role of microRNA146b in promoting mammary alveolar progenitor cell maintenance. J. Cell Sci. 2013; 126: 2446-2458.
17. Zhai PF, Wang F, Su R etal. The regulatory roles of microRNA-146b-5p and its target platelet-derived growth factor receptor α (PDGFRA) in erythropoiesis and megakaryocytopoiesis. J. Biol. Chem. 2014; 289: 22600-22613.
18. Xia H, Qi Y, Ng SS, Chen X, Li D etal. microRNA-146b inhibits glioma cell migration and invasion by targeting MMPs. Brain Res. 2009; 1269: 158-165.
19. Khanna N, Ge Y, Chen J. MicroRNA-146b promotes myogenic differentiation and modulates multiple gene targets in muscle cells. PLoS ONE 2014; 9: e100657.
20. Jiang W, Tang W, Geng Q, Xu X. Inhibition of Toll-like receptor 4 with vasoactive intestinal peptide attenuates liver ischemia-reperfusion injury. Transplant. Proc. 2011; 43: 1462-1467.
21. Jiang W, Hu M, Rao J, Xu X, Wang X, Kong L. Over-expression of Toll-like receptors and their ligands in small-for-size graft. Hepatol. Res. 2010; 40: 318-329.
22. Seki E, De Minicis S, Osterreicher CH etal. TLR4 enhances TGF-beta signaling and hepatic fibrosis. Nat. Med. 2007; 13: 1324-1332.
23. Shi H, Kokoeva MV, Inouye K, Tzameli I, Yin H, Flier JS. TLR4 links innate immunity and fatty acid-induced insulin resistance. J. Clin. Invest. 2006; 116: 3015-3025.
24. Ye D, Li FY, Lam KS etal. Toll-like receptor-4 mediates obesity-induced non-alcoholic steatohepatitis through activation of X-box binding protein-1 in mice. Gut 2012; 61: 1058-1067.
25. Tomita K, Tamiya G, Ando S etal. Tumour necrosis factor alpha signaling through activation of Kupffer cells plays an essential role in liver fibrosis of nonalcoholic steatohepatitis in mice. Gut 2006; 55: 415-424.
26. Tsujimoto T, Kuriyama S, Yamazaki M etal. Augmented hepatocellular carcinoma progression and depressed Kupffer cell activity in rat cirrhotic livers. Int. J. Oncol. 2001; 18: 41-47.
27. Vinciguerra M, Veyrat-Durebex C, Moukil MA, Rubbia-Brandt L, Rohner-Jeanrenaud F, Foti M. PTEN down-regulation by unsaturated fatty acids triggers hepatic steatosis via an NF-kappaBp65/mTOR-dependent mechanism. Gastroenterology 2008; 134: 268-280.
28. Stiles B, Wang Y, Stahl A etal. Liver-specific deletion of negative regulator PTEN results in fatty liver and insulin hypersensitivity [corrected]. Proc. Natl Acad. Sci. U.S.A. 2004; 101: 2082-2087.
29. Horie Y, Suzuki A, Kataoka E etal. Hepatocyte-specific PTEN deficiency results in steatohepatitis and hepatocellular carcinomas. J. Clin. Invest. 2004; 113: 1774-1783.